Description:
Home Page: arrowheadpharma.com
0HI3 Technical Analysis
177 East Colorado Boulevard
Pasadena,
CA
91105
United States
Phone:
626 304 3400
Officers
| Name | Title |
|---|---|
| Dr. Christopher R. Anzalone Ph.D. | CEO, Pres & Director |
| Mr. Kenneth A. Myszkowski | Chief Financial Officer |
| Mr. Patrick O'Brien J.D., PharmD | COO & Gen. Counsel |
| Dr. James C. Hamilton M.D., MBA | Sr. VP of Discovery & Translational Medicine |
| Dr. Javier San Martin M.D. | Chief Medical Officer |
| Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando |
| Dr. Vincent Anzalone CFA | Head of Investor Relations & VP |
| Mr. Howard Lovy | Director of Communications |
| Dr. Mark Seefeld | Head of Toxicology & VP |
| Ms. Tracie Oliver | Chief Commercial Officer |
Exchange: LSE
Country: GB
Currency: US Dollar ($)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0.1495 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 525 |